Biology and Treatment of Leukemia and Bone Marrow Neoplasms

1. Front Matter

   Pages i-viii

   PDF

2. Advances in Diagnosis and Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes

   • Raju K. Pillai, Michelle Afkhami

   Pages 1-16

3. Genetics and Diagnostic Approach to Lymphoblastic Leukemia/Lymphoma

   • Michelle Afkhami, Feras Ally, Vinod Pullarkat, Raju K. Pillai

   Pages 17-43

4. Acute Promyelocytic Leukemia: Update on Risk Stratification and Treatment Practices

   • Amandeep Salhotra, Matthew Mei

   Pages 45-55

5. Current and Emerging Therapies for Acute Myeloid Leukemia

   • Brian Ball, Matthew Mei, Salman Otoukesh, Anthony Stein

   Pages 57-73

6. Current Management and New Developments in the Treatment of ALL

   • Justin Darrah, Weili Sun

   Pages 75-96

7. CML Chapter

   • David Snyder

   Pages 97-114

8. Current Management and New Developments in the Treatment of Myelodysplastic Syndrome

   • Shukaib Arslan, Samer Khaled, Ryotaro Nakamura

   Pages 115-132

9. Chronic Lymphocytic Leukemia (CLL): Biology and Therapy

   • Tanya Siddiqi

   Pages 133-149

10. Biology and Current Treatment of Myeloproliferative Neoplasms

    • Haris Ali, Vinod Pullarkat, David Snyder

    Pages 151-165

11. Systemic Mastocytosis: Advances in Diagnosis and Current Management

    • Sheeja T. Pullarkat, Winnie Wu, Vinod Pullarkat

    Pages 167-178

12. Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL)

    • Geoffrey Shouse, Elizabeth Budde, Stephen Forman

    Pages 179-196

This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatments. There is a particular focus on the molecular abnormalities that are drivers of leukemia and on their detection by modern molecular techniques. Knowledge of the ways in which genomic and metabolic abnormalities in the hematologic neoplasms affect prognosis and treatment decision making is reviewed. Detailed attention is devoted to targeted therapies, including novel drugs, and to potential targets for future drug development. In addition, readers find in-depth discussion of cellular and antibody-based immunotherapies as well as the role of hematopoietic stem cell transplantation in the treatment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students.

• Acute and chronic Leukemias
• Bone Marrow Neoplasms
• Biology and Treatment
• Myelodysplastic and myeloproliferative Disorders
• Molecular Abnormalities
• Immunotherapies
• Hematopoietic Stem Cell Transplantation
• Targeted Therapies
• Adoptive T-Cell Therapy
• Systemic Mastocytosis

• Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, Duarte, USA

  Vinod Pullarkat, Guido Marcucci

Guido Marcucci, MD, is Chair and Professor in the Department of Hematologic Malignancies Translational Science and Professor in the Department of Hematology and Hematopoietic Stem Cell Transplantation at City of Hope (COH) Comprehensive Cancer Center in California. He is also Director of the Gehr Family Center for Leukemia Research at COH. Dr. Marcucci has conducted basic, translational, and clinical research in myeloid malignancies. His research focus has been on discovery of basic mechanisms of leukemogenesis, novel therapeutic targets, epigenetic and genetic prognostic biomarkers, and new drug development for AML and MDS. He has chaired several phase I, II, and III clinical trials as both single- and multi-institution studies within the oncology cooperative group Alliance (formerly known as CALGB), for which he is currently Vice-Chair of the Leukemia Committee and Member of the Leukemia Correlative Science Committee. Dr. Marcucci has published over 300 papers in peer-reviewed journals and has been uninterruptedly funded by the National Cancer Institute since 2001.

 

Vinod Pullarkat, MD, MRCP, is Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope National Medical Center in Los Angeles, California. Dr. Pullarkat’s clinical expertise is in the treatment of acute leukemia and other bone marrow neoplasms, including the use of hematopoietic stem cell transplantation.  He received his medical degree from University of Calicut, India, and undertook fellowship training in Hematology/Oncology at the University of Southern California, following which he served as Faculty in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope Medical Center and at the University of Southern California. Dr. Pullarkat’s research focuses especially on the biology of acute leukemia, including mechanisms of chemotherapy resistance, and the development of new therapies for acute leukemia. He has been Principal Investigator on various leukemia clinical trials and has published extensively in the fields of acute leukemia biology and therapy as well as hematopoietic stem cell transplantation.

Policies and ethics